Business
US-POLITICS-TRUMP-technology-Apple
President-elect Donald Trump and Apple CEO Tim Cook during a 2019 tour of a facility where Apple’s Mac Pros are assembled (Mandel Ngan/Getty Images)

What the Trump tariffs could mean for Apple

Only about 10% of iPhones are produced outside of China. Thankfully for Tim Cook, this isn’t his first rodeo.

President-elect Donald Trump said yesterday he would impose an additional 10% tariff on goods coming in from China. Ostensibly that’s bad news for Apple, which makes the vast majority of its products in China. As with everything Trump-related, there’s a lot of uncertainty about what will actually happen.

Here are some points to consider:

  • Thanks to CEO Tim Cook’s relatively amicable relationship with Trump, Apple was exempted from many of the China tariffs during Trump’s first presidency. It’s possible Apple could use that relationship to get an exemption once again — but this time, there’s a long line of other tech CEOs who are doing the same.

  • Apple currently has some US projects in the works, including an Arizona chip plant and a North Carolina campus that might soften Trump’s stance on the company’s China manufacturing. Cook famously — and smartly — said nothing when Trump incorrectly took credit for helping open a new Apple facility in the US. (It had been open for years.)

  • Last time around, Apple had argued that it couldn’t make its Apple Watch outside of China and meet American demand for the product. Such an argument might hold less weight now that the company has had a whole other presidency to figure ways out of China production.

  • Apple has moved some of its China production to India in a bid to lessen its reliance on China and, by extension, its tariffs. Despite that, only about 10% of iPhones are produced outside of China.

  • If Apple doesn’t secure another exemption, the impact on its gross margins could be significant, analysts say.

  • China is also an important market for Apple goods. If China retaliates against the tariffs with its own, that could also be bad news for Apple, which gets about 17% of its sales there.

  • So far the market doesn’t seem to be too worried about Apple. Its stock is currently up about 0.5% today.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.